| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 0 | 30 | 190 | 420 | 780 |
| Sales Growth | -100.00% | -84.21% | -54.76% | -46.15% | +132.37% |
| Net Income | -9,140 | -7,630 | -13,040 | -7,790 | -3,380 |
| Net Income Growth | -19.79% | +41.49% | -67.39% | -130.47% | -298.82% |
Hancock Jaffe Laboratories Inc (HJLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Hancock Jaffe Laboratories, Inc. is involved in developing and manufacturing bioprosthetic medical devices to treat cardiac and vascular diseases. Its product candidates consists of the porcine tissue based VenoValve, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency; CoreoGraft', a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery and a porcine tissue based heart valve, is an ideal candidate for pediatric aortic/mitral valve replacement. Hancock Jaffe Laboratories, Inc. is based in IRVINE, United States.